{"description":"Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution via expedited reporting (NCI AdEERs / CAeRs). All remaining CTCAEs collected by means other than expedited reporting are non-serious and are reported in the \"AE Other\" table. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":89,"description":"Patients receive low-dose carvedilol orally (PO) once daily (QD) or twice daily (BID) for 24 months.","id":"EG000","otherNumAffected":2,"otherNumAtRisk":89,"seriousNumAffected":0,"seriousNumAtRisk":89,"title":"Arm I (Carvedilol)"},{"deathsNumAffected":0,"deathsNumAtRisk":93,"description":"Patients receive placebo PO QD or BID for 24 months.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":93,"seriousNumAffected":0,"seriousNumAtRisk":93,"title":"Arm II (Placebo)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":89},{"groupId":"EG001","numAffected":0,"numAtRisk":93}],"term":"Dyspnea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":89},{"groupId":"EG001","numAffected":0,"numAtRisk":93}],"term":"Arthralgia"}],"timeFrame":"Up to 24 months after first dose of drug"}